Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by TechMooseon Mar 04, 2021 12:23pm

163 Views

Post# 32715736

Thanks for Insider Transactions Details CalgaryATE

Thanks CalgaryATE for posting that detailed summary showing where Wallace and Legault stand and how all this will most likely play out. This was bothering me a bit. More comfortable now and increasing my position while SH is still <$5.00. Just wanted you to know many of us appreciate these details provided on this board. GLTA #ATELongHaulers

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario